Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback

Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and longer acting therapies. Regeneron also co-markets and sells Dupixent, whose revenues exceeded >$4bn last quarter, with Regeneron earning >$1.4bn.